BioSpace News Archive

RedHill Biopharma Ltd. today reported its operational highlights and financial results for the fourth quarter and full year ended December 31, 2021.

BioLife Solutions, Inc. announced today an additional delay in the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”).

physIQ, a pioneer in digital medicine, and CellCarta, a global leader in precision medicine services, announce a strategic collaboration to undertake a groundbreaking study with the potential to revolutionize vaccine development.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), today announced that physicians at the Clinica Porto Azul in Barranquilla, Colombia successfully implanted the Company’s PortIO™ Intraosseous Infusion System in three patients—the first human implants of the device—as part of its IRB-approved first-in-human (FIH) clinical study of up to 40 patients.

Heron Therapeutics, Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) to commercialize ZYNRELEF (bupivacaine and meloxicam extended-release solution) for instillation into the surgical wound for postoperative analgesia after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty surgical procedures.

Nonalcoholic fatty liver disease is one of the leading causes of death worldwide. However, why premenopausal women are more resistant to NAFLD than men is currently unknown.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced publication of results from the Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in the New England Journal of Medicine (NEJM).

Amolyt Pharma today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the ongoing AZP-3601 clinical proof-of-concept trial in patients with hypoparathyroidism.

Manhattan Scientifics Inc. ( OTCQB: MHTX ), announces positive early results from Imagion Biosystems Cancer Diagnostic human study.

Innate Pharma SA, announced that the Company will hold a conference call on Thursday, March 24, 2022 at 2 p.m. CET / 9 a.m. ET.